文献速递脊柱关节炎其他结缔组织病

合并化脓性汗腺炎脊柱关节炎患者的独特表型与疾病负担

Distinct spondyloarthritis phenotypes and disease burden in patients with concomitant hidradenitis suppurativa.
PubMed 文献 · Semin Arthritis Rheum · 2026-08-19

多中心回顾性匹配病例对照研究显示,合并化脓性汗腺炎(HS)的脊柱关节炎(SpA)患者以中轴型为主,HLA-B27阳性率和放射学骶髂关节炎比例更低,但疾病活动度更高、共病更多、生物制剂使用种类更多且风湿科就诊更频繁,提示HS合并SpA具有独特表型和更高疾病负担。

要点

  • 合并HS的axSpA患者HLA-B27阳性率(46% vs 79%)和放射学骶髂关节炎(60% vs 86%)显著低于单纯axSpA。
  • 合并HS的axSpA患者ASDAS-CRP(3.0 vs 2.1)和CRP(11.3 vs 3.3 mg/L)显著更高。
  • 合并HS的axSpA患者活动性吸烟、高血压、焦虑抑郁及IBD更常见,且使用更多种生物制剂和csDMARD。

核心结论

  • 合并SpA与HS可能关联独特临床表型及更高疾病负担,导致治疗复杂性和医疗资源使用增加。
  • 研究支持HS可能属于SpA相关免疫介导表现谱系的假设,但需进一步研究验证。

研究设计与样本

  • 多中心、回顾性、匹配病例对照研究,病例为成人SpA且经皮肤科确诊HS,对照为无HS的SpA患者。
  • 共纳入39例病例和111例对照,提取既往三年电子病历数据。

主要发现

  • 病例中64%为中轴型SpA(axSpA),36%为外周型SpA(pSpA)。
  • 与对照相比,axSpA+HS患者HLA-B27阳性率更低(46% vs 79%,p=0.002),放射学骶髂关节炎更少(60% vs 86%,p=0.007),关节炎更常见(40% vs 23%,p=0.081)。
  • axSpA+HS患者活动性吸烟(68% vs 35%,p=0.006)、高血压(44% vs 17%,p=0.011)、焦虑抑郁障碍(36% vs 16%,p=0.046)及IBD(20% vs 3%,p=0.020)更常见。
  • axSpA+HS患者ASDAS-CRP更高(3.0 vs 2.1,p=0.003),CRP更高(11.3 vs 3.3 mg/L,p=0.001),使用不同生物制剂种类更多(p=0.028),csDMARD使用更频繁(52% vs 28%,p=0.018),风湿科就诊次数更多(中位9.0 vs 7.0,p=0.050)。

临床怎么用

  • 对SpA患者应关注HS共存可能,合并HS者需评估更高疾病活动度、共病负担及治疗复杂性。
  • 合并HS的axSpA患者可能HLA-B27阴性且影像学骶髂关节炎不典型,诊断时需综合判断。

局限性

  • 回顾性研究设计及样本量较小(39例病例)可能限制结论推广。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize the clinical phenotype and disease burden in patients with concomitant spondyloarthritis (SpA) and hidradenitis suppurativa (HS) versus patients with SpA alone. METHODS: We conducted a multicenter, retrospective and matched case-control study. Cases were adults with SpA and dermatologist‑confirmed HS; controls had SpA without HS. Data from the preceding three years were extracted from electronic medical records. RESULTS: We included 39 cases and 111 controls. Among cases, 64% had axial SpA (axSpA) and 36% peripheral SpA (pSpA). Compared with controls, patients with axSpA+HS had less HLA-B27 positivity (46%vs. 79%, p = 0.002), less radiographic sacroiliitis (60%vs. 86%, p = 0.007), and more frequent arthritis (40%vs. 23%; p = 0.081). Several comorbidities were more prevalent in axSpA+HS: active smoking (68%vs. 35%; p = 0.006), hypertension (44%vs. 17%; p = 0.011), and anxiety-depressive disorders (36%vs. 16%; p = 0.046). Among EMM, IBD was more frequent in axSpA+HS than in controls (20%vs. 3%; p = 0.020). Patients with axSpA+HS presented higher disease activity (ASDAS-CRP: 3.0 vs. 2.1, p = 0.003; CRP: 11.3 vs. 3.3 mg/L, p = 0.001), had received a greater number of different biologic agents (p = 0.028), showed more frequent csDMARD use (52%vs. 28%; p = 0.018), and had more rheumatology visits (median 9.0 vs. 7.0; p = 0.050). CONCLUSIONS: Concomitant SpA and HS appears to be associated with a distinct clinical phenotype and higher disease burden that translates into greater therapeutic complexity and healthcare utilization. These findings support the hypothesis that HS may form part of the broader spectrum of immune-mediated manifestations associated with SpA, although further investigation is required.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Cabanillas-Paredes M, Calvet J, Almirall M, et al. Distinct spondyloarthritis phenotypes and disease burden in patients with concomitant hidradenitis suppurativa. Semin Arthritis Rheum. 2026. PMID: 42664532. doi:10.1016/j.semarthrit.2026.153062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。